Contents

Search

afamitresgene autoleucel (Tecelra)

Indications: - metastatic synovial sarcoma (FDA-approved) Dosage: 250 mL afamitresgene autoleucel 40000000 cells/mL Injection

General

chimeric antigen-receptor (CAR) T-cell therapy; tisagenlecleucel; CTL019 (Kymriah)

References

  1. Winstead E FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma National Cancer Institure. Aug 27, 2025 https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4